INmune Bio, Inc.
INMB
$7.30
-$0.20-2.67%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -9.74M | -9.22M | -12.09M | -9.75M | -11.03M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | 6.00K | 15.00K | 24.00K | 34.00K |
| Total Other Non-Cash Items | 2.08M | 1.76M | 1.72M | 2.35M | 1.78M |
| Change in Net Operating Assets | 839.00K | -3.56M | 3.37M | -514.00K | 1.74M |
| Cash from Operations | -6.82M | -11.01M | -6.99M | -7.89M | -7.48M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -2.50M | -2.50M | -2.50M | -2.50M |
| Issuance of Common Stock | 5.27M | 422.00K | 12.29M | 15.50M | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 5.27M | -2.08M | 9.79M | 13.00M | -2.50M |
| Foreign Exchange rate Adjustments | -35.00K | 461.00K | -323.00K | -44.00K | 130.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.59M | -12.63M | 2.48M | 5.07M | -9.85M |